Unassociated Document
d the
UNITED
STATES SECURITIES AND
EXCHANGE
COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): July
4, 2006
GAMMACAN
INTERNATIONAL, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
0-32835
(Commission
File Number)
33-0956433
(IRS
Employer Identification No.)
29
Jerusalem Street., 554210 Kiryat Ono, Israel
(Address
of principal executive offices and Zip Code)
Registrant's
telephone number, including area code: 972
3 738 2616
11
Ben Gurion St., 54100 Givat Shmuel, Israel
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure
On
July
4, 2006, Maariv, a daily newspaper in Israel printed an article discussing
GammaCan International, Inc.’s business. A copy of the article is filed as
Exhibit 99.1 to, and incorporated by reference in, this report. In accordance
with Regulation FD, this current report is being filed to publicly disclose
all
information that was provided in the article. This report under Item 7.01 is
not
deemed an admission as to the materiality of any information in this report
that
is required to be disclosed solely by Regulation FD.
Item
8.01 Other Events
The
management of GammaCan International, Inc. reviewed the article by Maariv after
it was printed.vTo avoid any doubt the management of GammaCan International,
Inc. would like to add the following clarifications which more accurately
reflect the statements Mr. Schnegelsberg made:
|
·
|
While
Mr. Zeev
Bronfeld was mentioned as being a major share holder of GammaCan
International, Inc. he was not discussed in the context of any
financings.
|
|
·
|
To
address the change in emphasis to VitiGam from GCAN 101, Mr.
Schnegelsberg stated that GammaCan
would put all its efforts into developing VitiGam. Based on VitiGam’s
specific anti- melanoma activity seen in in
vitro
and in animal experiments as well as VitiGam’s anticipated safety profile
(comparable to that of GCAN101) GammaCan
anticipates VitiGam to be a substantially improved drug over GCAN101.
|
|
·
|
Mr.
Schnegelsberg in his discussion about potential markets suggested
that the
annual therapy cost for biologics today is between $50,000 and $80,000.
He
further suggested that some exceptionally active biologics could
command
premium pricing in the $100,000 range. VitiGam pricing was not
discussed.
|
|
·
|
GammaCan
received the approval of the BIRD Foundation for a $1,000,000 grant.
Under
this grant GammaCan International, Inc. and Life Therapeutics, Inc.
(and
not the entity identified in the article) would partner in a joint
study
of VitiGam.
|
Item
9.01 Financial Statements and Exhibits.
Exhibit
Number
|
|
Description
|
99.1
|
|
Article
printed in the Maariv Business Section on July 4,
2006
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
GAMMACAN
INTERNATIONAL, INC.
|
|
|
|
/s/
Patrick Schnegelsberg
|
|
Patrick
Schnegelsberg Chief Executive Officer
|
|
|
|
Date:
July 7, 2006
|